Want to join the conversation?
$AVGO 3Q15 Call: R&D expenses were $245MM and SG&A expenses were $85MM. This resulted in total operating expenses of $330MM, $5MM below AVGO's prior guidance, primarily because of cost synergies from the Emulex transactions being realized faster than expected. As a percentage of sales, R&D was 14% and SG&A was 5% of net revenue.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.